Month: March 2026

Diversified Energy Company (NYSE:DEC; LSE:DEC) announced on November 3, 2025 a dividend in respect of the third quarter ended September 30, 2025 in the amount of 29 cents per share (the “Q3 2025 Dividend”.) The Company will pay the Q3 2025 Dividend on March 31, 2026, to those shareholders on the register on February 27, 2026.  The Company announces that shareholders who have elected to receive their dividends in GBP sterling will receive an equivalent dividend payment of 21.471 pence per share, based on the March 10, 2026 exchange rate of GBP 0.74039 =US $1.00. For further information, please contact:Diversified Energy Company- +1 973 856 2757Doug Kris dkris@dgoc.comSenior Vice President, Investor Relations & Corporate Communications www.div.energy   FTI Consulting dec@fticonsulting.comU.S. & UK Financial Public...

COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the second tranche of the planned buy-back program, under which the Company intends to repurchase own shares for up to DKK 500 million during 2026. The first tranche, completed in early February 2026, comprised buy-back of shares for DKK 150 million. The second tranche will comprise buy-back of shares for DKK 200 million, also to be held as treasury stock for the purpose of adjusting the capital structure. The share buy-back program is initiated pursuant to the authorization granted at the annual general meeting on April 9, 2025, and in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation. Bavarian...

COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today published its annual report for 2025. The consolidated, audited results were in line with the preliminary results announced on February 12, 2026. The report is attached and available on www.bavarian-nordic.com. “Our 2025 annual report confirms the strong preliminary results reported last month and we are well underway in the execution of our plans for 2026 to deliver continued growth in our Travel Health business. Organic growth in our core products, rabies and TBE, remains strong, and is further stimulated by the continued global launch of our chikungunya vaccine,” said Paul Chaplin, President and CEO of Bavarian Nordic. “2026 marks the first year where revenues from Travel Health will surpass our Public Preparedness business, which is expected to normalize after...

Utrecht, 12 March 2026 Aalberts N.V. announces the successful completion of regulatory approvals and closing conditions, finalising the divestment of BROEN A/S (Broen), headquartered in Denmark, generating an annual revenue of approximately EUR 82 million with 500 employees. In December 2025, Aalberts announced that an agreement was reached to divest 100% of the shares of Broen. Broen will become part of new strategic ownership, fully active in its core business. We would like to thank all employees of Broen for their loyalty and ongoing efforts during the many years of Aalberts’ ownership. This transaction is part of the divestment programme as per our ‘thrive 2030’ strategy. Stéphane Simonetta (CEO) comments: “We will continue to rebalance our portfolio with clear strategic choices and disciplined capital allocation to ensure leadership...

Michelle C. WernerPhoto of Michelle C. Werner, EVP, President of North AmericaPARIS, FRANCE, 12 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Michelle C. Werner as Executive Vice President (EVP), President of North America, effective 23 March 2026. Michelle will serve on the Executive Leadership Team (ELT) and will report directly to Ipsen’s Chief Executive Officer (CEO), David Loew. “I am very pleased to welcome Michelle to Ipsen and to the Executive Leadership Team. She brings a wealth of experience in leading teams both in the U.S. and around the world and has a deep understanding of the United States and all the great opportunities that this market offers for Ipsen at a moment when we are accelerating the growth of our portfolio in rare diseases, oncology and neurosciences. These are...